 Infection with human papillomavirus HPV has been clearly established as the necessary cause of cervical cancer. The current Phase 3b study is designed to assess the immunogenicity and safety of a commercially available vaccine co-administered with GlaxoSmithKline Biologicals HPV vaccine GSK580299 in healthy female subjects. 